James Jenkins, MD
Interventional Cardiology · New Orleans, LANPI 1851321996
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $211,147 of the $234,995 with a category attached, or 89.9%. Abbott accounts for 95.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $79,021 and has fallen 97.9% since, to $1,676 in 2025. Among interventional cardiology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $765.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$223K
- Edwards Lifesciences$4K
- Abiomed$2K
- Boston Scientific$1K
- Philips North America LLC$697
- Medtronic$686
- plus $2K from 23 others
Across 227 payments — averaging $4353.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$337K
- Abbott$211K
- Recor Medical Inc$168K
- Cardiovascular Systems Inc.$137K
- Angiodynamics, Inc.$43K
- Inspiremd Ltd$39K
- plus $53K from 3 others
What the payments were for
- Consulting fees$211,14790%
- Grants$270%
- Travel & lodging$16,4937%
- Food & beverage$7,2193%
- Entertainment$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 157 | $223,489 |
| Edwards Lifesciences | 35 | $4,271 |
| Abiomed | 16 | $2,356 |
| Boston Scientific | 9 | $1,400 |
| Philips North America LLC | 9 | $697 |
| Medtronic(2 entities) | 18 | $686 |
| W. L. Gore & Associates, Inc. | 3 | $408 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $342 |
| Johnson & Johnson | 11 | $292 |
| Novo Nordisk | 5 | $113 |
| Endologix LLC | 1 | $98 |
| Angiodynamics, Inc. | 2 | $98 |
| Amgen | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 4 | $87 |
| Stryker | 2 | $80 |
| Livanova USA, Inc. | 3 | $77 |
| Pfizer | 4 | $76 |
| Imperative Care, Inc | 1 | $74 |
| Boehringer Ingelheim | 2 | $49 |
| Sanofi | 1 | $34 |
| AstraZeneca | 2 | $31 |
| Cook Medical LLC | 2 | $27 |
| Cardiac Dimensions, Inc. | 1 | $24 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Inquis Medical, Inc. | 1 | $16 |
| Truvic Medical, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| Acutus Medical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$71,038
- AMPLATZER$49,061
- AMPLATZER AMULET$40,460
- AMPLATZER TALISMAN$21,449
- SUPERA$19,818
- Omnilink Elite vascular stent system$19,250
- Impella$2,049
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,624
- EVOQUE$310
- GORE CARDIOFORM Septal Occluder$278
- Protege RX$159
- NAVITOR$149
- XIENCE V$135
- VIABAHN VBX Balloon Expandable Endoprosthesis$130
- XARELTO$125
- Resolute$123
- Turbo Elite$120
- GENERAL - STRUCTURAL HEART$112
- (6582) Visions 035$109
- Epic Stented Tissue Valve$109
How this compares
$234,995 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $9,771 |
| ClopidogrelClopidogrel Bisulfate | 30 | $356 |
| Atorvastatin Calcium | 16 | $144 |
| Prednisone | 12 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $9,77114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in New Orleans
- Rajan PatelNew Orleans$517K
- Stephen RameeNew Orleans$56K
- Jose Tafur SotoNew Orleans$44K
- Jose WileyNew Orleans$34K
- Zach RozenbaumNew Orleans$18K
- Aashish GuptaNew Orleans$18K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Agostino IngraldiLafayette$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.